Passage Bio Inc (PASG) Stock Price, Quote & News

Company Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic late...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 866 0311

Website: www.passagebio.com

Address:

One Commerce Square, 2005 Market Street 39th Floor, Philadelphia, United States

Few_erish Mar. 31 at 7:42 PM

$PASG holding up better than I thought

0 · Reply

notreload_ai Mar. 31 at 2:37 PM

Oppenheimer just started coverage on $PASG with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026. https://notreload.xyz/xy/oppenheimer-sees-1b-potential-in-passage-bio-pbft02-for-ftd/

0 · Reply

LilJimmy007 Mar. 31 at 2:26 PM

$PASG 30 dolla PT slapped on this

0 · Reply

topstockalerts Mar. 24 at 1:17 PM

Pre Market Top Gainers $PAVS $FEED $UGRO $ANNA $PASG

0 · Reply

JoshThe3rd Mar. 13 at 4:41 PM

$PASG Annoying price action. Not joking that I view the r/r as -30%/+500% on FDA update in 1H 2026.

0 · Reply

OfficialStocktwitsUser Mar. 11 at 3:01 PM

$PASG RSI: 45.98, MACD: -0.6037 Vol: 0.34, MA20: 8.73, MA50: 11.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

erevnon Mar. 4 at 7:27 PM

Canaccord Genuity maintains Passage Bio $PASG at Buy and lowers the price target from $67 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

semserus Mar. 3 at 9:09 PM

$PASG Passage Bio press release (PASG): Q4 GAAP EPS of -$4.09. Cash and cash equivalents were $46.3 million as of December 31, 2025, as compared to cash, cash equivalents, and marketable securities of $76.8 million as of December 31, 2024. The company expects current cash and cash equivalents to fund operations through 1Q 2027.

0 · Reply

OfficialStocktwitsUser Feb. 26 at 1:34 AM

$PASG RSI: 37.42, MACD: -0.8426 Vol: 1.10, MA20: 9.66, MA50: 11.56 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BDE_Worldwide Feb. 20 at 8:19 PM

$PRLD low float turd 💩 . But happy to ride along as this gets squeezed like so many other R/S bios that have lost 99% of investors long term capital.. see $PASG for reference.. 🚀 💥

1 · Reply

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Feb 19, 2026, 7:00 AM EST - 6 weeks ago

Passage Bio to Participate in Upcoming Investor Conferences

Nov 10, 2025, 4:15 PM EST - 5 months ago

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Nov 5, 2025, 7:00 AM EST - 5 months ago

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 14, 2025, 7:00 AM EDT - 6 months ago

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

Aug 28, 2025, 7:00 AM EDT - 7 months ago

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 8 months ago

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Jul 10, 2025, 7:00 AM EDT - 9 months ago

Passage Bio Announces 1-for-20 Reverse Stock Split

Jun 23, 2025, 7:00 AM EDT - 10 months ago

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

May 13, 2025, 7:00 AM EDT - 11 months ago

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Mar 4, 2025, 7:00 AM EST - 1 year ago

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Jan 10, 2025, 7:00 AM EST - 1 year ago

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Nov 6, 2024, 7:00 AM EST - 1 year ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 10, 2024, 7:52 AM EDT - 1 year ago

Passage Bio Welcomes Tom Kassberg to Board of Directors

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 2 years ago

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

May 14, 2024, 7:00 AM EDT - 2 years ago

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Apr 22, 2024, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 4, 2024, 7:00 AM EST - 2 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Feb 27, 2024, 7:00 AM EST - 2 years ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 31, 2024, 7:30 AM EST - 2 years ago

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 20, 2023, 7:00 AM EST - 2 years ago

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Nov 17, 2023, 4:30 PM EST - 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 13, 2023, 7:00 AM EST - 2 years ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

Oct 20, 2023, 4:30 PM EDT - 2 years ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

Aug 7, 2023, 7:15 AM EDT - 2 years ago

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

Jun 5, 2023, 7:00 AM EDT - 3 years ago

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 11, 2023, 7:00 AM EDT - 3 years ago

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

Apr 21, 2023, 4:01 PM EDT - 3 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 17, 2023, 7:00 AM EDT - 3 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Mar 6, 2023, 7:00 AM EST - 3 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Feb 28, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Feb 24, 2023, 7:00 AM EST - 3 years ago

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Feb 15, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Dec 14, 2022, 7:00 AM EST - 3 years ago

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Nov 10, 2022, 7:00 AM EST - 3 years ago

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

Oct 10, 2022, 7:00 AM EDT - 3 years ago

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

Few_erish Mar. 31 at 7:42 PM

$PASG holding up better than I thought

0 · Reply

notreload_ai Mar. 31 at 2:37 PM

0 · Reply

LilJimmy007 Mar. 31 at 2:26 PM

$PASG 30 dolla PT slapped on this

0 · Reply

topstockalerts Mar. 24 at 1:17 PM

Pre Market Top Gainers $PAVS $FEED $UGRO $ANNA $PASG

0 · Reply

JoshThe3rd Mar. 13 at 4:41 PM

$PASG Annoying price action. Not joking that I view the r/r as -30%/+500% on FDA update in 1H 2026.

0 · Reply

OfficialStocktwitsUser Mar. 11 at 3:01 PM

0 · Reply

erevnon Mar. 4 at 7:27 PM

Canaccord Genuity maintains Passage Bio $PASG at Buy and lowers the price target from $67 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

semserus Mar. 3 at 9:09 PM

0 · Reply

OfficialStocktwitsUser Feb. 26 at 1:34 AM

0 · Reply

BDE_Worldwide Feb. 20 at 8:19 PM

$PRLD low float turd 💩 . But happy to ride along as this gets squeezed like so many other R/S bios that have lost 99% of investors long term capital.. see $PASG for reference.. 🚀 💥

1 · Reply

BillionerOfKing Feb. 17 at 12:02 PM

$PASG Current Stock Price: $9.22

0 · Reply

Aawilliam2003 Feb. 11 at 2:22 PM

$PASG FTD is a tough one to solve. Raising progranulin levels apparently doesn’t work as $ALEC showed. Does anyone think this could be different for some reason?

0 · Reply

ShippingSherpa Feb. 9 at 2:58 PM

$PASG Passive components or semiconductor; volume-driven, cyclical business.

1 · Reply

ElowenLun Jan. 31 at 2:19 PM

$PASG Data shows that a growing number of institutions are reporting positions in PASG, and certain large holders (like Lynx1 Capital) have meaningful stakes. That can signal confidence from professional investors.

1 · Reply

ElowenLun Jan. 31 at 2:18 PM

$PASG

0 · Reply

juliano777 Jan. 23 at 2:58 PM

$PASG Why doesn't the CEO own any shares?

0 · Reply

juliano777 Jan. 22 at 3:35 PM

$PASG It's time to buy... 13,87$

2 · Reply

OfficialStocktwitsUser Jan. 16 at 5:57 AM

$PASG RSI: 59.32, MACD: 1.7950 Vol: 3.62, MA20: 13.37, MA50: 10.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Mart7810 Jan. 14 at 2:10 AM

$PASG thx for the run! Maybe I'll buy back

0 · Reply

McLarkin Jan. 13 at 9:03 PM

$PASG feels like nearer fair value - all things considered.... exciting space

0 · Reply

semserus Jan. 13 at 7:29 PM

$PASG Despite the current "sell-off," analysts remain largely bullish on the company’s long-term prospects: Analyst Consensus: The stock maintains a Strong Buy rating from most analysts, with an average price target of $34.50. Cash Runway: Passage Bio recently updated its corporate presentation, noting that its current cash reserves should fund operations through the first quarter of 2027.

0 · Reply

semserus Jan. 13 at 7:21 PM

$PASG Reason the Price is Dropping ... As of January 13, 2026, the stock is trading around $15.66, down about 12% today. This follows a period of extreme volatility: Overbought Conditions: The stock surged over 83% in the two weeks leading up to January 8. Technical indicators like the RSI (Relative Strength Index) showed the stock was heavily overbought, making a "correction" or price drop likely. Profit-Taking: After approaching its 52-week high of $20.00, investors likely began selling to lock in gains, leading to the sharp 9.8% drop on Monday and further declines today.

0 · Reply

Market Cap	25.92M
Revenue (ttm)	0.00
Net Income (ttm)	-45.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	18,200
Avg Vol	40,626
Day's Range	N/A - N/A
Shares Out	3.21M
Stochastic %K	93%
Beta	1.77
Analysts	Strong Sell
Price Target	$30.67